MetaTrader
  • Markets
  • Charts & Ideas
  • Algo
  • News
  • Store
  • Brokers
  • Download
  • Economic Calendar
  • Trading Signals
  • WebTerminal
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Italiano Italiano
  • Türkçe Türkçe
Neuropace, Inc. Common Stock

NPCE

#2528
Neuropace, Inc. Common Stock
14.5800
-0.95%
Sector:
Base:
Profit Currency:
Daily Range
14.5800
14.5800
Year Range
9.2200
17.8960
Daily Change
-0.95%
Monthly Change
-9.97%
6 month change
+37.81%
Year Change
+37.81%
Previous Close
14.7200
Open
14.5800
Bid
Ask
Low
14.5800
High
14.5800
Volume
30
  1. Markets
  2. US Stock Market
  3. Healthcare
  4. NPCE
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
Value 2021202220232024 TTM

News

Zacks Zacks
LIVN NPCE
2026.02.25
LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates
Zacks Zacks
SGHT NPCE
2026.02.25
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Zacks
NPCE TFX
2026.02.24
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks Zacks
PACB NPCE
2026.02.12
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
Investing Investing
NPCE
2026.02.02
NeuroPace stock price target raised to $20 from $19 at Leerink Partners
Investing Investing
NPCE
2026.01.27
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright
Seeking Alpha Seeking Alpha
NPCE
2026.01.15
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Investing Investing
NPCE
2026.01.14
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue
Investing Investing
NPCE
2026.01.13
NeuroPace reports 25% revenue growth for 2025, projects steady growth
Investing Investing
NPCE
2025.12.17
NeuroPace seeks FDA approval to expand RNS System for epilepsy treatment
Investing Investing
NPCE
2025.12.09
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy
Investing Investing
NPCE
2025.12.08
NeuroPace reports 77% seizure reduction in epilepsy device trial

Markets

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Charts & Ideas

  • Trading Ideas
  • Education Ideas
  • Charts

MQL5 Community

  • Market
  • Signals
  • Forum
  • Articles
  • CodeBase

News

  • US Stock Market
  • Currencies
  • Cryptocurrencies
  • Metals
  • Commodities

Brokers

  • All Brokers
  • Forex
  • Stock
  • Metals
MetaTrader 5
MQL5 Channels
Economic Calendar
Disclaimer and Risk Disclosure Terms of Use Contacts and Requests Legal
Copyright 2000-2026, MetaQuotes Ltd